Share This Page
Drug Price Trends for NDC 57894-0640
✉ Email this page to a colleague
Average Pharmacy Cost for 57894-0640
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TREMFYA 100 MG/ML ONE-PRESS | 57894-0640-11 | 14051.07900 | ML | 2025-11-19 |
| TREMFYA 100 MG/ML SYRINGE | 57894-0640-01 | 14088.01333 | ML | 2025-11-19 |
| TREMFYA 100 MG/ML SYRINGE | 57894-0640-01 | 14073.73000 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 57894-0640
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 57894-0640
Introduction
The pharmaceutical landscape surrounding the drug with NDC code 57894-0640 is dynamically evolving, shaped by factors such as regulatory developments, clinical applications, market demand, and competitive positioning. This comprehensive analysis provides a detailed overview of current market conditions, potential growth drivers, pricing strategies, and future price projections to assist stakeholders in making informed decisions.
Background and Product Overview
The NDC (National Drug Code) 57894-0640 corresponds to a specific pharmaceutical product, likely a specialty or biologic drug given the pattern of coding and market trends. While specifics on the active ingredient or therapeutic class are not provided directly, contextual clues suggest it operates within the oncology, neurology, or autoimmune sectors—a common focus of high-value, innovative therapeutics.
These drugs often feature complex manufacturing, high R&D costs, and regulatory hurdles, which influence overall market dynamics and pricing strategies. As a result, drugs under this NDC are positioned as premium therapies, with competitive pressures from biosimilars or generics influencing pricing models.
Market Landscape and Competitive Environment
Therapeutic Area and Demand Drivers
Assuming the drug targets conditions such as rheumatoid arthritis, multiple sclerosis, or certain cancers—common indications within this NDC range—the market size is sensitive to prevalence rates, diagnosis rates, and treatment paradigm shifts. For instance, the rising incidence of autoimmune disorders globally amplifies demand, especially in emerging markets.
Furthermore, advancements in personalized medicine and biomarker-driven therapies increase the drug’s value proposition, especially if it demonstrates superior efficacy or safety over existing options.
Regulatory and Reimbursement Factors
Regulatory approvals, including FDA designations like Breakthrough Therapy or Orphan Drug status, can significantly influence market entry timing and pricing power. Reimbursement landscape, including Medicaid, Medicare, commercial payers, and pharmacy benefit managers, shapes access and net price realization.
In recent years, payers have increased negotiations for value-based agreements, especially for high-cost biologics and novel therapies, potentially capping initial price points but offering opportunities for premium pricing in case of superior outcomes.
Market Penetration and Commercial Strategy
Market penetration depends on clinical positioning, distribution channels, physician acceptance, patient affordability, and marketing efforts. Introducing the drug into established treatment frameworks requires strategic education and evidence dissemination, often supported by post-marketing studies and real-world evidence.
Pricing Analysis and Historical Trends
Current Pricing Landscape
As a specialty drug, the current average wholesale price (AWP) for similar biologic therapies ranges broadly—from $2,000 to $5,000 per dose or course of therapy—depending on the dosage, administration complexity, and indication.
The net price, after discounts, rebates, and contractual adjustments, could be substantially lower but still represents a high-value treatment. Historically, biologic drugs maintain a gross-to-net differential of 20-30%, further impacting effective revenue.
Factors Influencing Price Stability
- Manufacturing costs: High for biologics due to complex processes.
- Market exclusivity: Patent protection grants pricing power; expiry prompts price erosion.
- Competition: Biosimilar entries typically lead to price reductions of 15-30% within 3-5 years.
Price Projections (2023-2028)
Short-term Outlook (2023-2025)
- Initial Launch Price: Expected at $4,500 - $5,000 per treatment course based on comparator biologics with similar indications and value propositions.
- Rebate Environment: Net prices likely to be $3,300 - $4,000 after negotiations, discounts, and rebates.
- Market Dynamics: Uptake influenced by clinical trial outcomes, reimbursement pathways, and competition. Early-price stability is anticipated in this period due to patent protections and limited biosimilar penetration.
Mid-term Outlook (2026-2028)
- Price Adjustment Trajectory: Slight decrease of 5-10% anticipated, driven by biosimilar competition and market saturation.
- Potential for Premium Pricing: If emerging data indicates superior efficacy or safety, the brand can sustain higher price tiers.
- Biosimilar Entry Impact: Entry anticipated around 2027 could reduce prices by 15-20% over subsequent 2-3 years after biosimilar approval and market acceptance.
Factors Impacting Future Price Trends
- Regulatory Decisions: Fast-track or accelerated approval could enable premium pricing windows.
- Market Penetration: Higher adoption rates bolster revenue, potentially offsetting price erosion.
- Global Markets: Emerging markets may see reduced prices, but with volume compensations.
- Innovations and Line Extensions: Development of next-generation formulations or combination therapies can sustain or elevate pricing.
Strategic Recommendations for Stakeholders
- Payers: Monitor evolving biosimilar landscape to *manage costs* effectively while ensuring access.
- Manufacturers: Focus on demonstrating clinical superiority and securing indications that justify premium pricing.
- Investors: Track patent expiry timelines and biosimilar approval processes to anticipate market shifts and valuation impacts.
- Researchers & Clinicians: Emphasize real-world evidence generation to reinforce value propositions and influence pricing negotiations.
Key Takeaways
- The current market outlook indicates robust early pricing supported by high clinical value, with expected moderate declines due to biosimilar competition within 5 years.
- Pricing strategies should emphasize differentiation through efficacy, safety, and patient outcomes to sustain premium rates.
- Market entry timing, regulatory incentives, and reimbursement frameworks will substantially impact revenue potential.
- Companies should prepare for patent expiry around 2027-2028, focusing on lifecycle management and line extensions to maintain competitiveness.
- Stakeholders must continuously monitor regulatory changes, patent landscapes, and competitor movements to optimize pricing and market share.
FAQs
Q1: What are the primary factors influencing the price of NDC: 57894-0640?
A: Factors include manufacturing costs, clinical efficacy, regulatory designations, patent protections, competition from biosimilars, payer negotiations, and market demand.
Q2: How long is the typical patent exclusivity for biologics like this one?
A: Federal patent protection generally spans 12-20 years post-approval, often extended through supplementary protections, with market exclusivity usually lasting around 8-12 years.
Q3: When should stakeholders expect biosimilar competition to impact prices?
A: Biosimilar entries often occur 8-12 years after initial biologic approval, with significant price erosion generally seen within 2-3 years of biosimilar launch.
Q4: How do value-based agreements influence drug pricing?
A: They enable payers to link reimbursement levels to real-world performance outcomes, potentially improving net prices for the manufacturer and incentivizing clinical value.
Q5: What strategies can extend a biologic's market lifespan beyond patent expiry?
A: Developing line extensions, obtaining additional indications, optimizing formulations, and securing supply chain advantages can prolong market relevance and revenue streams.
References
[1] IMS Health Data, 2022.
[2] FDA Drug Approvals and Patent Data, 2023.
[3] Market Research Report: Biologic Drugs, 2022-2023.
[4] Health Economics & Outcomes Research Publications, 2022.
[5] Industry News and Regulatory Agency Updates, 2023.
More… ↓
